{"disease":{"id":"uterine-serous-carcinoma","name":"uterine serous carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06476808","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04590248","title":"A Study of Adavosertib as Treatment for Uterine Serous Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04814108","title":"A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT06369155","title":"Azenosertib in Uterine Serous Carcinoma: Biomarker Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Joyce Liu, MD","has_results":false},{"nct_id":"NCT03552471","title":"Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04080284","title":"Trial of Maintenance With Niraparib- Uterine Serous Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Northwell Health","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}